3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
28
Paclitaxel
24
Carboplatin
19
Bevacizumab
14
Specimen Handling
13
Magnetic Resonance Spectroscopy
10
Doxorubicin
8
Cisplatin
8
Biopsy
8
olaparib
7
lenvatinib
7
Taxes
7
Letrozole
7
Megestrol Acetate
6
Fulvestrant
6
durvalumab
5
dostarlimab
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Gemcitabine
5
trastuzumab deruxtecan
4
abemaciclib
4
X-Rays
4
Trastuzumab
4
Tirzepatide
4
Progestins
4
Oxaliplatin
4
Immunoglobulin G
4
Fluorouracil
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
STX-478
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled